Ironwood Pharmaceuticals (NASDAQ:IRWD Shareholders Incur Further Losses as Stock Declines 7.2% This Week, Taking Three-year Losses to 51%
Ironwood Pharmaceuticals (NASDAQ:IRWD Shareholders Incur Further Losses as Stock Declines 7.2% This Week, Taking Three-year Losses to 51%
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long term Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shareholders know that all too well, since the share price is down considerably over three years. Sadly for them, the share price is down 51% in that time. And more recent buyers are having a tough time too, with a drop of 41% in the last year. Shareholders have had an even rougher run lately, with the share price down 19% in the last 90 days.
如果您正在建立一個良好的多元化股票組合,那麼您的一些選擇很可能表現不佳。 這幾年來,長揸Ironwood醫藥股份有限公司(納斯達克:IRWD)股票的股東深有感觸,因爲股價在這一時期大幅下跌。遺憾的是,這段時間內股價下跌了51%。最近買家也遭遇了艱辛境地,去年股價下跌了41%。股東們最近的日子更難熬了,股價在最近90天內下跌了19%。
Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.
考慮到過去一週對股東來說是艱難的,讓我們調查一下基本面並看看我們能學到什麼。
To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.
引用本傑明·格雷厄姆的話:短期內市場是一個投票機,但長期來看它是一個稱重機。評估公司周邊環境的情緒變化的一種有缺陷但合理的方法是將每股收益(EPS)與股價進行比較。
Ironwood Pharmaceuticals saw its share price decline over the three years in which its EPS also dropped, falling to a loss. Extraordinary items contributed to this situation. Due to the loss, it's not easy to use EPS as a reliable guide to the business. However, we can say we'd expect to see a falling share price in this scenario.
在這3年的時間裏,Ironwood醫藥的每股收益也下降了,導致股價下跌併產生了非常規項目。 由於虧損,很難將每股收益作爲業務的可靠指南。 然而,在這種情況下,我們可以說我們期望看到股價下跌。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
該公司的每股收益(隨時間的推移)如下圖所示(單擊可查看確切數字)。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240804/0-c3f831a7a04d4e4963d1ea9864b03ad0-0-f91490f189d019842ea38fd305271239.png/big)
We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. This free interactive report on Ironwood Pharmaceuticals' earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.
我們喜歡看到內部人在過去十二個月中購買了股票。 話雖如此,大多數人認爲盈利和營業收入增長趨勢更能反映業務的實際情況。 如果您想進一步調查該股票,Ironwood醫藥的盈利,營業收入和現金流的免費互動報告是一個不錯的起點。
A Different Perspective
不同的觀點
Ironwood Pharmaceuticals shareholders are down 41% for the year, but the market itself is up 19%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 6% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand Ironwood Pharmaceuticals better, we need to consider many other factors. Take risks, for example - Ironwood Pharmaceuticals has 3 warning signs (and 1 which shouldn't be ignored) we think you should know about.
Ironwood醫藥的股東們今年損失了41%,但市場本身上漲了19%。 然而,要記住,即使最好的股票有時也會在十二個月的時間內表現不佳。 遺憾的是,去年的表現可能表明存在未解決的問題,因爲它比過去半個世紀的年化損失還要嚴重。 我們認識到,羅斯柴爾德男爵曾說過投資者應該在“街道上爆發衝突時”購買股票,但我們警告投資者首先要確定他們正在購買質量較高的業務。 跟蹤較長時間的股價表現總是很有趣的。 但是,要更好地了解Ironwood醫藥,我們需要考慮許多其他因素。 例如承擔風險 - Ironwood醫藥有3個警示(和1個不應忽視的警示)是我們認爲您應該了解的。
Ironwood Pharmaceuticals is not the only stock that insiders are buying. For those who like to find lesser know companies this free list of growing companies with recent insider purchasing, could be just the ticket.
Ironwood醫藥並不是內部人正在購買的唯一股票。 對於那些喜歡尋找較少知名的公司的人來說,這個免費的增長公司列表是最近有內部人購買的,可能正是您要尋找的。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。